Gadoliniumtoxicity.org

10/05/2026

In order to get serum gadolinium measured, the MD can order CPT code 83018, which as of May 2025 now includes Gadolinium.

09/05/2026

Safety concerns about Gadolinium contrast agents were raised for patients with normal kidney function in 2014, when researchers discovered that gadolinium could remain in patients’ brains and could accumulate with each additional dose of contrast that they received. Gadolinium has been found in bone, skin, and other organs and tissues of patients with normal kidney function.

https://www.center4research.org/health-risks-of-gbcas/?utm_source=chatgpt.com

09/05/2026

Nailfold capillaroscopy:

The widespread occurrence of adverse alterations in the microcirculation, seen using nailfold capillaroscopy, is extensively found in multiple syndromes sharing the common injury of intensely damaged endothelium. For further info see 2025 review paper on this technique: https://www.preprints.org/manuscript/202505.2356

These diseases include systemic sclerosis, long covid, and raynauds, amongst others.

Is Gadolinium toxicity microvascular injury ready to be added to this list ? An example of a gadolinium toxic patient with abnormal nail-fold capillaroscopy is shown below. Studies could be done on affected patients, as microvascular injury is likely to be a central mechanism of damage in Gadolinium toxicity.

Gadolinium toxic patient with abnormal nailfold capillaroscopy, showing:
- vessel dropout
- vessel tortuosity
- vessel sclerosis / thickening

16/04/2026

Real patient, > 2yrs since last Gadolinium contrast injection, normal renal function,
Blood > 50 x URL
Urine > 75 x URL
* GADOLINIUM CONTAINING MRI CONTRAST AGENTS ARE INHERENTLY UNSAFE & OVERTLY HARMFUL *

11/04/2026

Mitochondrial dysfunction due to retained gadolinium

The retention of the heavy metal, gadolinium, after a Gadolinium-Based Contrast Agent-assisted MRI may lead to a symptom cluster termed Gadolinium Deposition...

24/02/2026

Contrast Media–driven Anthropogenic Gadolinium: Knowns and Unknowns

This title is a 2024 peer-reviewed review article in the journal “Radiology”.

It examines the environmental and clinical implications of anthropogenic gadolinium, a toxic by-product of the medical use of gadolinium-based contrast agents (GBCAs) in magnetic resonance imaging.

The authors discuss emerging mitigation strategies, including development of virtual or synthetic contrast techniques that reduce reliance on gadolinium. They advocate continued monitoring of gadolinium in biological tissues such as bone and call for integrated medical–environmental research to anticipate long-term effects.

This article frames anthropogenic gadolinium as an instructive finding at the intersection of clinical harm, environmental responsibility, and much needed innovation to remove toxic gadolinium from our bodies and our environment.

Full text link:
https://pubs.rsna.org/doi/10.1148/radiol.240020

16/01/2026

Real patient, no history of renal failure, >2 years since last Gadolinium contrast injection, still poisoned.

31/12/2025

The top 4 offenders shown are banned or rarely used in Europe, but no similar restrictions in the US. Time for the FDA to catch up with the rest of the world and do the ethical thing.

21/12/2025

Gadolinium Deposition in the Brain: A Toxicological Reality, Not a Theoretical Risk

For more than two decades, reassurances from industry and regulatory bodies have framed gadolinium-based contrast agents (GBCAs) as biologically inert since they are chelated, rapidly excreted, and therefore clinically benign. This narrative has proven dangerously incomplete. It is now unequivocally established that gadolinium deposits in the human brain — including the dentate nucleus, globus pallidus, basal ganglia, and cerebellum — even in individuals with normal renal function. These findings, initially dismissed as “radiological curiosities,” have been repeatedly demonstrated across MRI signal changes, post-mortem elemental analysis with inductively coupled plasma mass spectrometry (ICP-MS). The persistence of gadolinium years after exposure directly contradicts early pharmacokinetic claims and raises unavoidable toxicological concerns.

What remains most troubling is not merely the presence of gadolinium, but the disconnect between deposition and accountability. Free gadolinium is a known neurotoxin, capable of disrupting calcium-dependent signaling, mitochondrial function, and microglial activation. Macrocyclic agents reduce but do not eliminate tissue retention, and linear agents demonstrably dechelate in vivo. Yet industry messaging continues to emphasize “lack of proven harm” rather than absence of biological effect — a semantic distinction that has real consequences for patients who develop neurological, autonomic, inflammatory, and connective tissue syndromes following repeated exposure.

The reassurance offered by large pharmaceutical stakeholders mirrors earlier chapters in medical history, where widespread exposure preceded mechanistic understanding: asbestos, thalidomide, organophosphates. In each case, early patient reports were minimized, pathophysiology lagged behind clinical observation, and regulatory action followed only after incontrovertible harm became impossible to ignore. Gadolinium deposition disease, nephrogenic systemic fibrosis, and emerging evidence of central nervous system involvement suggest we are witnessing another such inflection point with this Gadolinium toxicity. The burden of proof should no longer rest on injured patients to demonstrate harm beyond doubt, but on manufacturers and regulators to explain why a persistent heavy metal in neural tissue should be presumed harmless by default.

MRI Brain Image of a patient with symptomatic Gadolinium Toxicity. Gadolinium can be seen as light grey regions within the deep basal ganglia and cerebellum. These are highly metabolically active neural tissue regions.

21/12/2025

Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role

Domingo, Semelka et al 2025

Full text link :
https://link.springer.com/article/10.1007/s00204-025-04124-x

This peer-reviewed review article focuses on gadolinium-based contrast agent (GBCA) toxicity. It synthesizes the latest evidence on retention, emerging biological interactions (including nanoparticle formation), mechanisms beyond classic transmetallation, and clinical manifestations such as gadolinium deposition in brain, bone, and skin even in patients with normal renal function.
It also discusses regulatory aspects and future research directions for safer alternatives and biomarkers. 

• GBCAs are not biologically inert; stability assumptions are being challenged.
• Endogenous nanoparticle formation may drive tissue retention.
• This review proposes avenues for future work.